Can MitoQ Rejuvenate Vascular Function in Healthy Older Adults?
Written by Georgia Truman (MSc), Molecular and Cellular Biology. Reviewed by Dr. Siobhan Mitchell (PhD), Neuroscience.
Vascular ageing is a progressive, largely asymptomatic process that precedes clinically overt cardiovascular disease by decades. Endothelial dysfunction, reduced nitric oxide (NO) bioavailability, and increasing arterial stiffness emerge early in this trajectory and are strongly predictive of later cardiovascular events. Researchers from the University of Boulder Colorado examined whether chronic supplementation with Mitoquinol, a mitochondria-targeted antioxidant, could intervene at this upstream biological level by reducing mitochondrial oxidative stress in the ageing endothelium.
What you'll learn:
Why endothelial dysfunction and arterial stiffness are early, predictive markers of cardiovascular ageing
How mitochondrial oxidative stress limits nitric oxide bioavailability—and why mitochondria‑targeted antioxidants differ from conventional approaches
The effects of 6 weeks of Mitoquinol supplementation on endothelial-dependent dilation and aortic sitffness.
What selective changes in oxidised LDL—but not inflammatory markers—reveal about Mitoquinol’s mechanism
Vascular function is a key marker of longevity
Vascular function predicts cardiovascular risk long before the development of clinically diagnosable disease. Brachial artery flow-mediated dilation (BAFMD) is the most widely used non-invasive measurement of endothelial health and declines progressively with age, even in otherwise healthy individuals. Epidemiological data indicate that each 1% reduction in FMD is associated with an approximately 13% increase in cardiovascular event risk.
Because these changes occur upstream of structural disease, vascular function has become a central target within geroscience and cardiovascular prevention research. Interventions that preserve or restore endothelial function in later life therefore address risk at its earliest actionable stage.
How does vascular function impact cardiovascular health?
The mechanistic basis of vascular ageing is well-characterised. Ageing endothelial cells exhibit increased mitochondrial reactive oxygen species (mtROS) production, which rapidly scavenges nitric oxide before it can mediate vasodilation. Reduced NO bioavailability promotes vasoconstriction, inflammation, and pro-thrombotic signalling, which leads to the development of clotting and atherosclerosis
In parallel, arterial stiffening—quantified via aortic pulse wave velocity (PWV)—increases cardiac afterload and impairs coronary perfusion. Reduced FMD and elevated PWV reinforce one another, creating a feed-forward loop that elevates the risk of cardiovascular disease, stroke, and all-cause mortality. Whether this mitochondria-driven dysfunction is modifiable in otherwise healthy older adults remains a critical clinical question.
What current tools and therapies can improve vascular function?
Lifestyle interventions remain foundational. Aerobic exercise improves endothelial function through shear stress–mediated endothelial nitric oxide synthase (eNOS) activation, while Mediterranean-style dietary patterns provide modest complementary benefit.
Pharmacological agents such as ACE inhibitors and statins primarily manage downstream risk factors rather than the mitochondrial processes driving endothelial ageing itself. Conventional antioxidant supplementation has also disappointed in clinical trials; vitamins C and E have shown minimal benefit, likely because their activity is largely cytosolic and fails to address mtROS at its principal site of generation within the mitochondrial inner membrane.
How does Mitoquinol improve heart health?
Mitoquinol was developed to overcome this mitochondrial limitation. Its lipophilic triphenylphosphonium (TPP⁺) moiety exploits the mitochondrial membrane potential (approximately −180 mV), enabling several-hundred-fold accumulation within the mitochondrial matrix.
By scavenging superoxide at its site of overproduction, Mitoquinol preserves nitric oxide signalling while avoiding indiscriminate suppression of physiological redox signalling. This mechanistic precision distinguishes mitochondria-targeted antioxidants from broad-spectrum compounds and provides a plausible explanation for their divergent clinical effects.
Mitoquinol has been used in over 9 heart-health studies, and has shown consistent favourable benefits for improving endothelial function in healthy, and unhealthy older adults.
How does Mitoquinol impact arterial dilation and stiffness?
In 2018, researchers from Colorado Boulder sought to understand the role that supressing mtROS has on vascular function. They conducted a 6-week randomised, double-blind crossover trial, 20 healthy adults aged 60–79 received 20 mg of Mitoquinol daily. They found that brachial artery flow-mediated dilation improved by 42% relative to placebo (P < 0.05), a substantial gain in a cohort without overt cardiovascular disease.
Among participants with elevated baseline arterial stiffness, Mitoquinol also significantly reduced aortic PWV, suggesting benefits may be greatest in those with more advanced subclinical dysfunction.
How does this research support the mitochondrial theory of vascular aging?
A mechanistically informative feature of the study was the inclusion of an acute supratherapeutic challenge (160 mg). Following the placebo phase, this single high dose acutely improved FMD. When given after chronic Mitoquinol supplementation, the same dose produced no further effect.
This pattern indicates that sustained supplementation had already resolved the mtROS-driven constraint on endothelial function. The absence of an acute response after chronic treatment provides in vivo evidence that mitochondrial oxidative stress is not merely associated with vascular ageing, but represents a primary and reversible driver.
What are the clinical implications for practitioners?
A 42% improvement in FMD in healthy older adults represents a clinically meaningful shift in vascular risk, particularly given the well-established relationship between FMD and cardiovascular outcomes. Importantly, Mitoquinol also reduced levels of oxidized LDL-cholesterol by 13%. In a recent review article, Dr Ahotupa argues that lipid oxidation product specifically, not merely LDL-cholesterol, are most dangerous for the development of plaques and thickening of blood vessels. Reducing the lipid oxidation product burden will also help to prevent the progression of vascular-related disease.
By targeting both endothelial function and lipid oxidation, Mitoquinol mesylate provides an attractive therapy for treating sub-clinical vascular dysfunction in older individuals.
Read the full article: Chronic Supplementation With a Mitochondrial Antioxidant (Mitoquinol) Improves Vascular Function in Healthy Older Adults – PubMed
DOI: 10.1161/HYPERTENSIONAHA.117.10787
